SEC Form 4 · accession 0001209191-16-129919
Cascadian Therapeutics, Inc. · CASC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Christopher S Henney
Officer — Interim CEO and President · Director
Period of report
Jun 24, 2016
Accepted (ET)
Jun 28, 2016 · 5:11 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001412067
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Share Units (RSU)F1,F2 | — | Jun 24, 2016 | A | 54,347 | A | — | — | Common Stock | 54,347 | 54,347 | D |
Explanation of responses
- F1Approximately 75% of each RSU represents a contingent right to receive approximately 0.75 share of the issuer's Common Stock upon vesting and approximately 25% represents a contingent right to receive cash upon vesting, which cash will be used to facilitate such holder's satisfaction of U.S. federal income tax obligations in connection with the vesting of the RSUs.
- F2100% vests on the one-year anniversary of the Transaction Date, subject to acceleration under certain circumstances.